What oncologists need and require from nuclear medicine

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 10, 2008, Pages 1761-1765

  Pantaleo, M A ^a   Fanti, S ^a   Nannini, M ^a   Boschi, S ^a   Nanni, C ^a   Maleddu, A ^a   Rubello, D ^b   Biasco, G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

18F FDG PET; Nuclear medicine; Oncology; Oncology PET; Oncology therapy PET oncology

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER RESEARCH; CANCER SCINTISCANNING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR;

DIAGNOSTIC IMAGING; ITALY; MEDICAL ONCOLOGY; MOLECULAR PROBES; NEEDS ASSESSMENT; NUCLEAR MEDICINE; PATIENT CARE TEAM;

EID: 52449105376     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0825-y     Document Type: Editorial

References (41)

1. BA Weir MS Woo G Getz S Perner L Ding R Beroukhim 2007 Characterizing the cancer genome in lung adenocarcinoma Nature 450 7171 893 898
2. J Shen C Behrens II Wistuba L Feng JJ Lee WK Hong 2006 Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western array and immunohistochemistry Cancer Res 66 11194 11206
3. CH Chung PS Bernard CM Perou 2002 Molecular portraits and the family tree of cancer Nat Genet 32 Suppl 533 540
4. CB Moeder JM Giltnane M Harigopal A Molinaro A Robinson K Gelmon 2007 Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome J Clin Oncol 25 5418 5425
5. M Scartozzi I Bearzi R Berardi A Mandolesi G Fabris S Cascinu 2004 Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies J Clin Oncol 22 4772 4778
6. RS Kerbel 2005 Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed Cancer Cell 8 269 271
7. E Segal CB Sirlin C Ooi AS Adler J Gollub X Chen 2007 Decoding global gene expression programs in liver cancer by noninvasive imaging Nat Biotechnol 25 675 680
8. RF Ozols RS Herbst YL Colson J Gralow J Bonner WJ Curran Jr 2007 Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology J Clin Oncol 25 146 162
9. CP Raut M Posner J Desai JA Morgan S George D Zahrieh 2006 Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors J Clin Oncol 24 2325 2331
10. E Van Cutsem M Nowacki I Lang S Cascinu I Shchepotin J Maurel 2007 Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial J Clin Oncol 25 18S 4000
11. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch I Smith 2005 Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer N Engl J Med 353 1659 1672
12. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson 2005 Trastuzumab plus adjuvant chemotherapy in HER-2 positive breast cancer N Engl J Med 353 1673 1684
13. R DeMatteo K Owzar R Maki P Pisters M Blackstein C Antonescu 2007 Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001 Proc Am Soc Clin Oncol 25 18S
14. N Thatcher A Chang P Parikh J Rodrigues Pereira T Ciuleanu 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527 1537
15. FA Shepherd J Rodrigues Pereira T Ciuleanu EH Tan V Hirsh S Thongprasert 2005 Erlotinib in previously treated non small-cell lung cancer N Engl J Med 353 123 132
16. CR Antonescu P Besmer T Guo K Arkun G Hom B Koryotowski 2005 Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 11 4182 4190
17. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
18. H Young R Baum U Cremerius K Herholz O Hoekstra AA Lammertsma 1999 Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 1773 1782
19. H Choi C Charnsangavej SC Faria HA Macapinlac MA Burgess SR Patel 2007 Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 1753 1759
20. WA Weber R Figlin 2007 Monitoring cancer treatment with PET/CT: does it make a difference J Nucl Med 48 36S 44S
21. KY Chung J Shia NE Kemeny M Shah GK Schwartz A Tse 2005 Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 1803 1810
22. M Moroni S Veronese S Benvenuti G Marrapese A Sartore-Bianchi F Di Nicolantonio 2005 Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Lancet Oncol 6 279 286
23. HJ Lenz E Van Cutsem S Khambata-Ford RJ Mayer P Gold P Stella 2006 Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines J Clin Oncol 24 4914 4921
24. F Di Fiore F Blanchard F Charbonnier F Le Pessot A Lamy MP Galais 2007 Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy Br J Cancer 96 1166 1169
25. M Scartozzi I Bearzi C Pierantoni A Mandolesi F Loupakis A Zaniboni 2007 Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy J Clin Oncol 25 3930 3935
26. JG Paez PA Jänne JC Lee S Tracy H Greulich S Gabriel 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500
27. TJ Lynch DW Bell R Sordella S Gurubhagavatula RA Okimoto BW Brannigan 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 2139
28. MC Heinrich CL Corless GD Demetri CD Blanke M von Mehren H Joensuu 2003 Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 4342 29
29. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145
30. MA Pantaleo M Nannini A Maleddu S Fanti V Ambrosini C Nanni 2008 Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy Cancer Treat Rev 34 103 121
31. W Cai K Chen L He Q Cao A Koong X Chen 2007 Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody Eur J Nucl Med Mol Imaging 34 850 858
32. Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, et al. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging. 2008;in press.
33. E Mishani G Abourbeh O Jacobson S Dissoki R Ben Daniel Y Rozen 2005 High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors J Med Chem 48 5337 5348
34. A Pal A Glekas M Doubrovin J Balatoni M Namavari T Beresten 2006 Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography Mol Imaging Biol 8 262 277
35. PM Smith-Jones DB Solit T Akhurst F Afroze N Rosen SM Larson 2004 Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors Nat Biotechnol 22 701 706
36. PM Smith-Jones D Solit F Afroze N Rosen SM Larson 2006 Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET J Nucl Med 47 793 796
37. MA Pantaleo S Fanti PL Lollini S Boschi G Biasco 2007 PET detection of epidermal growth factor receptor in colorectal cancer: a real predictor of response to cetuximab treatment Eur J Nucl Med Imaging 34 1510 1511
38. KE Kil YS Ding KS Lin D Alexoff SW Kim C Shea 2007 Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec) Nucl Med Biol 34 153 163
39. DR Collingridge VA Carroll M Glaser EO Aboagye S Osman OC Hutchinson 2002 The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography Cancer Res 62 5912 5919
40. DS Boss RV Olmos M Sinaasappel JH Beijnen JH Schellens 2008 Application of PET/CT in the development of novel anticancer drugs Oncologist 13 25 38
41. C Nanni D Rubello S Fanti 2007 Role of small animal PET for molecular imaging in pre-clinical studies Eur J Nucl Med Mol Imaging 34 1819 1822